Pharmacotheraphy and guidelines for Parkinson's syndrome;Das Parkinson-syndrom: Pharmakotherapie und leitlinien

Pharmazie in Unserer Zeit

Volumn 35, Issue 3, 2006, Pages 242-248

  Baas, Horst ^a  

^a Klinikum Stadt Hanau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; BUDIPINE; CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DECARBOXYLASE INHIBITOR; DIHYDROERGOCRYPTINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE; ENZYME INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; DRUG HALF LIFE; DRUG MECHANISM; DYSKINESIA; HUMAN; IDIOPATHIC DISEASE; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; TREMOR; DRUG ANTAGONISM; REVIEW;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CHOLINERGIC ANTAGONISTS; ENZYME INHIBITORS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33744988582     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200600172     Document Type: Article

References (32)

1. Gerlach, M.H., Reichmann, H., Riederer, P.: Die Parkinson-Krankheit. Grundlagen, Klinik, Therapie. 2. Auflage, Springer Verlag, Wien (2003).
2. Goetz, C.G., Poewe, W., Rascol, O., et al.: Evidence based medical review update: pharmacological and surgical treatments of Parkinson's disease. Mov. Disorders 20 (2005), 523-539.
3. Oertel, W.H., et al.: Parkinson-Syndrome. In: Diener H.C. et al. (Hrsg.): Leitlinien für Diagnostik und Therapie in der Neurologie, 3. Auflage. Georg Thieme Verlag, Stuttgart-New York (2005).
4. 3 dopamine receptors. Parkinsonism Relat. Disord. 11 (2005), S25-S29.
5. Widnell, K.: Pathophysiology of motor fluctuations in Parkinson's disease. Mov. Disord. 20 (2005), S17-S22.
6. Lundqvist, C., Nystedt, T., Reiertsen, O., Grotli, R., Beiske, A.G.: Continuous treatment with levodopa of Parkinson disease. Tidsskr. Nor. Laegeforen. 125 (2005), 2638-2640.
7. Nilsson, D., Nyholm, D., Aquilonius, S.M.: Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol. Scand. 104 (2001), 343-348.
8. Storch, A., Trenkwalder, C., Oehlwein, C., Winkelmann, J., Polzer, U., Hundemer, H.P., Schwarz, J.: High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. Parkinsonism Relat. Disord. 11 (2005), 393-398.
9. Halloway, R.G., Shoulson, I., Fahn, S., et al.: Pramipexole vs. Levodopa as initial treatment for Parkinson's disease. Arch. Neurol. 61 (2004), 1044-1053.
10. Eggert, K., Odin, P., Gasser, T., et al.: Herzklappenerkrankungen und andere fibrotische Reaktionen als Nebenwirkung von Dopaminagonisten. DÄB 102 (2005), 1-2.
11. Paus, S., Brecht, H.M., Koster, J., Seeger, G., Klockgether, T., Wullner, U.: Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov. Disord. 8 (2003), 659-667.
12. Arnulf, I.: Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev. 9 (2005), 185-200.
13. Henchcliffe, C., Schumacher, H.C., Burgut, F.T.: Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert. Rev. Neurother. 5 (2005), 811-821.
14. Lees, A.: Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22 (2005), 731-740.
15. Rascol, O.: Rasagiline in the pharmacotherapy of Parkinson's disease - a review. Expert Opin. Pharmacother. 6 (2005), 2061-2075.
16. Rascol, O., Brooks, D.J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., Tolosa, E.; LARGO study group: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARCO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 (2005), 947-954.
17. Clarke, C.E.: Rasagiline for motor complications in Parkinson's disease. Lancet 365 (2005), 914-916.
18. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62 (2005), 241-248.
19. Widnell, K.L., Comella, C.: Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov. Disord. 20 (2005), S30-S37.
20. Deane, K.H., Spieker, S., Clarke, C.E.: Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. 4 (2004), CD004554.
21. Schrag, A.: Entacapone in the treatment of Parkinson's disease. Lancet Neurol. 4 (2005), 366-370.
22. Keating, G.M., Lyseng-Williamson, K.A.: Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 19 (2005), 165-184.
23. Thomas, A., Iacono, D., Luciano, A.L., Armellino, K., Di Iorio, A., Onofrj, M.: Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 75 (2004), 141-143.
24. Crosby, N.J., Deane, K.H., Clarke, C.E.: Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst. Rev. 2 (2003) CD003467.
25. Crosby, N., Deane, K.H., Clarke, C.E.: Amantadine in Parkinson's disease. Cochrane Database Syst. Rev. 1 (2003), CD003468.
26. Przuntek, H., Bittkau, S., Bliesath, H., et al.: Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch. Neurol. 59 (2002), 803-806.
27. Roach E.S.: Initial Parkinson disease therapy: levodopa, dopamine agonists, or both? Arch. Neurol. 61 (2004), 1972-1973.
28. Waters C.: Other pharmacological treatments for motor complications and dyskinesias. Mov. Disord. 20 (2005), S38-S44.
29. Morgante, .L, Epifanio, A., Spina, E., et al.: Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol. 27 (2004), 153-156.
30. Fernandez, H.H., Donnelly, E.M., Friedman, J.H.: Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov. Disord. 19 (2004), 831-833.
31. Pollak, P., Tison, F., Rascol, O., et al.: Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry. 75 (2004), 689-695.
32. Juncos, J.L., Roberts, V.J., Evatt, M.L., et al.: Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov. Disord. 19 (2004), 29-35.